Q-Line Biotech Ltd
Incorporated in 2010, Q-Line Biotech Ltd.
is engaged in the business of developing, manufacturing and marketing a diverse
range of reagents.[1]
- Market Cap ₹ 1,281 Cr.
- Current Price ₹ 549
- High / Low ₹ 600 / 431
- Stock P/E 22.2
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 23.3 %
- ROE 26.4 %
- Face Value ₹ 10.0
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 313 | 341 | |
| 242 | 242 | |
| Operating Profit | 72 | 99 |
| OPM % | 23% | 29% |
| 17 | 5 | |
| Interest | 15 | 19 |
| Depreciation | 7 | 11 |
| Profit before tax | 67 | 74 |
| Tax % | 29% | 23% |
| 47 | 57 | |
| EPS in Rs | 300.95 | 34.99 |
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 38% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 26% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 2 | 16 |
| Reserves | 188 | 231 |
| 158 | 213 | |
| 101 | 87 | |
| Total Liabilities | 449 | 547 |
| 73 | 141 | |
| CWIP | 59 | 15 |
| Investments | 18 | 17 |
| 298 | 374 | |
| Total Assets | 449 | 547 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 22 | 21 | |
| -75 | -29 | |
| 46 | 36 | |
| Net Cash Flow | -7 | 28 |
| Free Cash Flow | -48 | -14 |
| CFO/OP | 42% | 47% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 97 | 136 |
| Inventory Days | 225 | 258 |
| Days Payable | 139 | 142 |
| Cash Conversion Cycle | 183 | 252 |
| Working Capital Days | 52 | 65 |
| ROCE % | 23% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Capacity Utilization - Clinical Chemistry/Rapid/Elisa Kits (Unit 3) % |
|
|||
| Geographic Revenue Mix - North India % |
||||
| Instrument Revenue Share % |
||||
| Number of Customers Served count |
||||
| Number of Distributors count |
||||
| Reagent Revenue Share % |
||||
| Capacity Utilization - Selectra Pro M Analyzers (Unit 2) % |
||||
| Manufacturing Capacity - Selectra Pro M Analyzers (Unit 2) units per year |
||||
Extracted by Screener AI
Documents
Announcements
-
Reply to Clarification- Financial results
2 July 2026 - Exchange had sought clarification from Q-Line Biotech Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On …
-
Analysts/Institutional Investor Meet/Con. Call Updates
30 June 2026 - Q-Line Biotech held FY26 earnings call; revenue rose 9% to ₹341.7 crore, PAT to ₹55.7 crore.
-
Analysts/Institutional Investor Meet/Con. Call Updates
30 June 2026 - Q-Line Biotech Limited has informed about Schedule of meet proposed to be held on 03rd July 2026 at 03:30 PM
-
Analysts/Institutional Investor Meet/Con. Call Updates
27 June 2026 - Q-Line Biotech Limited has informed about Schedule of meet of Group of Investors
-
Clarification - Financial Results
25 June 2026 - Exchange has sought clarification from Q-Line Biotech Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On …
Concalls
-
Jun 2026Transcript PPT
Business Profile:[1]
Q-Line Biotech is an Indian in-vitro
diagnostics (IVD) company engaged
in developing, manufacturing, marketing
and distributing diagnostic reagents, consumables, point-of-care (POC)
devices and diagnostic equipment.
The company primarily serves
diagnostic laboratories, hospitals
and medical colleges through
a B2B distribution-led model.